"alpha-Galactosidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-galactosides including galactose oligosaccharides, galactomannans, and galactolipids.
Concept/Terms
alpha-Galactosidase- alpha-Galactosidase
- alpha Galactosidase
- Melibiase
- alpha-Galactosidase A
- alpha Galactosidase A
- alpha-Galactosidases
- alpha Galactosidases
Below are MeSH descriptors whose meaning is more general than "alpha-Galactosidase".
Below are MeSH descriptors whose meaning is more specific than "alpha-Galactosidase".
This graph shows the total number of publications written about "alpha-Galactosidase" by people in Harvard Catalyst Profiles by year, and whether "alpha-Galactosidase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1999 | 2 | 0 | 2 |
2001 | 2 | 0 | 2 |
2002 | 1 | 2 | 3 |
2005 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2007 | 1 | 0 | 1 |
2008 | 2 | 1 | 3 |
2009 | 2 | 1 | 3 |
2010 | 4 | 0 | 4 |
2011 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 1 | 2 | 3 |
2014 | 1 | 1 | 2 |
2017 | 0 | 1 | 1 |
2019 | 2 | 2 | 4 |
2020 | 1 | 1 | 2 |
2021 | 1 | 2 | 3 |
2022 | 0 | 1 | 1 |
2023 | 1 | 4 | 5 |
Below are the most recent publications written about "alpha-Galactosidase" by people in Profiles.
-
Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [18F]AGAL Targeting Alpha-Galactosidase A Enzyme for Fabry Disease. Molecules. 2023 Oct 18; 28(20).
-
Cluster analysis of kidney function decline among males with Fabry disease in a large United States electronic health records database. Nephrol Dial Transplant. 2023 09 29; 38(10):2350-2357.
-
c.376A>G, (p.Ser126Gly) Alpha-Galactosidase A mutation induces ER stress, unfolded protein response and reduced enzyme trafficking to lysosome: Possible relevance in the pathogenesis of late-onset forms of Fabry Disease. Mol Genet Metab. 2023 11; 140(3):107700.
-
Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab. 2023 07; 139(3):107603.
-
Striking a balance in Fabry disease research: Mitigating the statistical dilemma arising from small sample size and modest event frequency in rare disorders. Int J Cardiol. 2023 08 01; 384:52-53.
-
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry. Mol Genet Metab. 2023 02; 138(2):106967.
-
Beneficial screening of Fabry disease in patients with hypohidrosis. J Dermatol. 2022 Feb; 49(2):308-312.
-
Burden of Valvular Heart Disease in Patients with Fabry Disease. J Am Soc Echocardiogr. 2022 02; 35(2):236-238.
-
X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay. Clin Exp Nephrol. 2021 Nov; 25(11):1224-1230.
-
Misfolding of Lysosomal a-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat. Int J Mol Sci. 2020 Oct 07; 21(19).